STAT+: GSK to buy Bellus Health for $2 billion, gaining chronic cough drug
LONDON — GSK said Tuesday it would purchase Bellus Health for $2 billion, adding a…
Category: biotechnology
Q&A: What does it mean when a clinical trial is delayed? More than you think
Frank David was just starting an independent research program on cell signaling in cancer and…
STAT+: A bellwether moment: Once a distant dream, gene therapy for Duchenne nears historic decision
Brent and Sabina Furbee could see something was wrong with their son, Emerson, even if…
STAT+: Moderna’s mRNA cancer vaccine shows promise in combination with melanoma drug
ORLANDO, Fla. — For years, early experimental results offered hope that scientists might be able…
Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion
Merck said Sunday that it will acquire Prometheus Biosciences for $10.8 billion, adding a pipeline…
Listen: How the legal battle over abortion could thwart research, plus: the FDA ‘bully pulpit’ and Moderna’s future
Is pharma facing an existential threat? How do you get CEOs to speak out? And…
STAT+: FDA staff leaned toward rejecting Sarepta gene therapy before top official intervened
Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene…
.jpg)
Opinion: Michael J. Fox: As a Parkinson’s patient, I felt a little left behind by biology’s century — until now
Last fall in STAT, Matt Herper questioned whether the biomedical research enterprise is really laying…
STAT+: A biotech upstart takes on cancer by crowdsourcing the immune system’s natural killers
No two people have quite the same immune system. And while that fact can make…
STAT+: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation
Amid an investigation of alleged research misconduct, Stanford University’s president took responsibility in an email…
Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case
South San Francisco biotech Genentech on Thursday announced that an internal review of misconduct allegations…
Listen: Illumina’s boardroom intrigue, the next big Alzheimer’s readout, & J&J’s creative lawyers
Is Illumina the Disney of biotech? Does the Texas two-step work after all? And can…
STAT+: To make immunotherapy safe for brain tumors, researchers will have to tackle new risks
The success of CAR-T immunotherapies against blood cancers has raised hope that CAR-T can bring…
STAT+: From a public library whiteboard, a $350 million biotech venture fund
A new biotech VC firm started by veterans of the industry began around a whiteboard…
STAT+: FTC tells Illumina to divest Grail, boosting Icahn’s case
The U.S. Federal Trade Commission on Monday ordered DNA sequencing giant Illumina to divest Grail,…
STAT+: A young boy’s nightmare diagnosis, and the $3 million one-time treatment that will likely save his life
When the long-awaited moment arrived, a nurse helped Adam Hess loosen a tiny plastic clamp…
STAT+: Vertex, CRISPR Therapeutics inch ahead of rival for genetic fix to sickle cell disease
The first CRISPR treatment for sickle cell disease has been submitted to the Food and…
STAT+: A devastating skin condition could soon get its first medication, as the frontiers of gene therapy expand
Wounds have been a constant fact of Aaron Owens’ life. His skin is so fragile…
STAT+: The biotech scorecard for the second quarter: 24 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
Listen: Biotech’s monkey shortage, the broken generics market, & conference cancel culture
What happened to the market for monkeys? Are some drugs too cheap? And why are…
STAT+: Former J&J exec, an in-demand free agent, takes the helm at privately held FogPharma
Mathai Mammen, who until recently led research at Johnson & Johnson, will become the CEO…
STAT+: New research may give geneticists a long-sought tool: a targeted protein delivery device
Mark Hurst just wanted to kill some bugs. A newly credentialed bacteriologist working for the…
Pressure is building on pharma and biotech companies to take climate action
As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies…
STAT+: With new study data, Intra-Cellular could expand use of approved mood-disorder treatment
Intra-Cellular Therapies, maker of an approved treatment for schizophrenia and bipolar depression, announced positive results…
STAT+: Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug
Viking Therapeutics, a small biotechnology company, said Tuesday that its experimental medicine led patients to…
STAT+: Novartis data set up multibillion-dollar battle over breast cancer drugs
Novartis announced data Monday that could set up one of the biggest marketing battles in…
STAT+: Bernie Sanders’ accidentally great drug pricing idea
When Moderna CEO Stéphane Bancel was called before a Senate committee last week to defend…
STAT+: Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
The Food and Drug Administration will convene a meeting of independent advisers to review a…
Why the world’s smallest wheelchairs are going unused
DALLAS — Inside Kelly Eakin’s garage in suburban Maryland, two of the world’s smallest wheelchairs…
Opinion: The surprising biomedical legacy of the Iraq War
Monday marked the 20th anniversary of the Iraq war, which resulted in an estimated 110,600…
Listen: Bancel v. Bernie, Sarepta’s FDA runaround, & Regeneron’s ever-growing blockbuster
What would Jonas Salk say if he were here right now? How do you know…
STAT+: FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
An independent panel of advisors to the Food and Drug Administration on Wednesday concluded that…
Opinion: The lesson biotech absolutely should not take from Silicon Valley Bank’s failure
As a five-time biotech CEO, I’ve guided my companies through recessions, supply chain disruptions, Wall…
STAT+: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
WASHINGTON — The future of Alzheimer’s treatments and coverage hung heavily over lawmakers’ Wednesday hearing…
STAT+: 89bio treatment reduces liver scarring in patients with NASH, meeting study goals
89bio said Wednesday that its experimental treatment improved liver scarring at more than three times…
STAT+: Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
A new obesity treatment being developed by Altimmune met goals for weight loss in a…
STAT+: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel
WASHINGTON — Moderna CEO Stéphane Bancel has some explaining to do. Bancel will appear alone…
STAT+: Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans
Karuna Therapeutics said Monday that its treatment for schizophrenia reduced psychosis reported by patients —…
Watch: P-value, an important measurement in clinical trials, explained
When testing new treatments, drugmakers must show that their formulation bears out better results than…
‘A safe place to fail’: ARPA-H chief on building a culture of risk-taking in science
Renee Wegrzyn has been assembling teams her whole career — in academia, industry, and government….
STAT+: Takeda autoimmune therapy shows effectiveness in key trial
Doctors and investors are getting their first glimpse of the data that compelled Takeda Pharmaceutical…
STAT+: Moderna CEO made $398 million in 2022, but still pledges to give most to charity
Moderna CEO Stéphane Bancel is starting to reap gargantuan gains from the stock he first…
STAT+: FDA to convene advisory panel for Sarepta’s gene therapy for Duchenne
In a sudden about-face, the Food and Drug Administration will hold a meeting of outside…
Listen: SVB’s long biotech shadow, pushy AI algorithms, & Icahn v. Illumina
Is AI dictating patient care? What happens when your bank falls apart? And can Illumina…
STAT+: Califf criticizes insurers for doing too little on drug research
WASHINGTON — FDA Commissioner Robert Califf wants private insurers to chip in on doing post-approval…
STAT+: CRISPR? Nah. A new startup bets on an old approach to gene editing
Before there was CRISPR, aspiring genome editors relied on an island of misfit, less elegantly…
Opinion: Drug developers navigating ‘biology’s century’ need a model. We made one
STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry…
STAT+: Amylyx’s ALS drug launch starts strong. That could be trouble for the FDA
Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question:…
STAT+: Veterans Health Administration will cover the newest Alzheimer’s drug
In an unexpected move, the Veterans Health Administration announced Monday that it will widely cover…
STAT+: Illumina has been ignoring its investors, but it can’t ignore Carl Icahn
Illumina, the DNA sequencing giant whose stock has fallen 40% in two years, already had…